Growth Metrics

Vertex Pharmaceuticals (VRTX) Notes Payables (2016 - 2017)

Vertex Pharmaceuticals (VRTX) has 2 years of Notes Payables data on record, last reported at $232.4 million in Q4 2017.

  • For Q4 2017, Notes Payables rose 216.55% year-over-year to $232.4 million; the TTM value through Dec 2017 reached $232.4 million, up 216.55%, while the annual FY2017 figure was $232.4 million, 216.55% up from the prior year.
  • Notes Payables reached $232.4 million in Q4 2017 per VRTX's latest filing, up from $190.3 million in the prior quarter.
  • Across five years, Notes Payables topped out at $232.4 million in Q4 2017 and bottomed at $73.4 million in Q4 2016.